NCT06059846Phase 3Completed

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Study sponsor: Spero Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-01-27Actual
Enrollment · participants1690Actual
Source updated2026-03-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Actual enrollment decreased by 958 participants

Before: 2648 participants (actual). After: 1690 participants (actual).

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of Participants With Overall Response at the Test-of-Cure (TOC) Visit. After: Measure: Number of Participants With Overall Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (Micro-ITT) Population.

Actual enrollment increased by 958 participants

Before: 1690 participants (actual). After: 2648 participants (actual).

Check registry source

· 1 field changed

Primary completion date changed

Before: 18 Jan 2025. After: 27 Jan 2025.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview